Genmab — Juni 2016
-
Derudover øgede Darzalex de generelle responsrater markant til 93 pct. mod 76 pct., fremgår det af meddelelsen fra Janssen.
-
-
Tak for link Helge, men lidt sjovt at det bliver fremlagt som nye data præsenteret fredag morgen - indtil videre har vi da ikke set noget nyt ift EHA abstract, der har været kendt længe http://learningcenter.ehaweb.org/eha/2016/21st/135349/meletios.a.dimopoulos.an.open-label.randomised.phase.3.study.of.daratumumab.html?f=m3
-
-
En hård dag hvis man ikke har de lange briller på.
-
Salgstal den 22 juni bliver rigtig gode, ved vi
-
Hvornår ved om Castor og Pollux får Priority Review?
-
Hvornår formodes det at ske?
-
Hvis der gives Priority Review skal FDA behandle ansøgningen inden for 6 mdr.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind